5-Fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma: A Phase II trial of the gynecologic oncology group

K. Y. Look, J. A. Blessing, H. B. Muss, Koenraad De Geest

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Twenty-one patients with recurrent epithelial ovarian carcinoma not amenable to cure with further surgery or radiotherapy were entered into a Phase II trial utilizing i.v. leucovorin at 20 mg/m2 followed by i.v. 5- fluorouracil at 425 mg/m2 administered daily for 5 days every 4 weeks for the first two courses and then every 5 weeks. Twenty-one patients were entered. Of these, 20 were eligible for toxicity assessment and 19 for response. Five had received prior radiotherapy, and all had received prior cisplatin-based chemotherapy. There was one patient response (5.3%; 95% confidence intervals for response of 0% to 26%). Toxicity was moderate with 5 of 20 (25%) grade 3 or 4 leukopenia, 12 of 20 (60%) grade 3 or 4 granulocytopenia, 1 of 20 (5%) grade 3 thrombocytopenia, 5 of 20 (25%) grade 3 GI toxicity, and 2 of 20 (10%) grade 3 neurotoxicity. There was one toxic death in a patient who developed granulocytopenia and pneumonia after her third course of treatment. This dose schedule of 5-fluorouracil and leucovorin has minimal activity in patients with recurrent epithelial ovarian carcinoma who have received prior cisplatin chemotherapy.

Original languageEnglish (US)
Pages (from-to)494-496
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number6
StatePublished - 1992
Externally publishedYes

Fingerprint

Leucovorin
Fluorouracil
Carcinoma
Agranulocytosis
Cisplatin
Radiotherapy
Therapeutics
Drug Therapy
Poisons
Leukopenia
Pneumonia
Appointments and Schedules
Confidence Intervals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{1e845913cb454b4fb05d16f3d181e728,
title = "5-Fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma: A Phase II trial of the gynecologic oncology group",
abstract = "Twenty-one patients with recurrent epithelial ovarian carcinoma not amenable to cure with further surgery or radiotherapy were entered into a Phase II trial utilizing i.v. leucovorin at 20 mg/m2 followed by i.v. 5- fluorouracil at 425 mg/m2 administered daily for 5 days every 4 weeks for the first two courses and then every 5 weeks. Twenty-one patients were entered. Of these, 20 were eligible for toxicity assessment and 19 for response. Five had received prior radiotherapy, and all had received prior cisplatin-based chemotherapy. There was one patient response (5.3{\%}; 95{\%} confidence intervals for response of 0{\%} to 26{\%}). Toxicity was moderate with 5 of 20 (25{\%}) grade 3 or 4 leukopenia, 12 of 20 (60{\%}) grade 3 or 4 granulocytopenia, 1 of 20 (5{\%}) grade 3 thrombocytopenia, 5 of 20 (25{\%}) grade 3 GI toxicity, and 2 of 20 (10{\%}) grade 3 neurotoxicity. There was one toxic death in a patient who developed granulocytopenia and pneumonia after her third course of treatment. This dose schedule of 5-fluorouracil and leucovorin has minimal activity in patients with recurrent epithelial ovarian carcinoma who have received prior cisplatin chemotherapy.",
author = "Look, {K. Y.} and Blessing, {J. A.} and Muss, {H. B.} and {De Geest}, Koenraad",
year = "1992",
language = "English (US)",
volume = "15",
pages = "494--496",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - 5-Fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma

T2 - A Phase II trial of the gynecologic oncology group

AU - Look, K. Y.

AU - Blessing, J. A.

AU - Muss, H. B.

AU - De Geest, Koenraad

PY - 1992

Y1 - 1992

N2 - Twenty-one patients with recurrent epithelial ovarian carcinoma not amenable to cure with further surgery or radiotherapy were entered into a Phase II trial utilizing i.v. leucovorin at 20 mg/m2 followed by i.v. 5- fluorouracil at 425 mg/m2 administered daily for 5 days every 4 weeks for the first two courses and then every 5 weeks. Twenty-one patients were entered. Of these, 20 were eligible for toxicity assessment and 19 for response. Five had received prior radiotherapy, and all had received prior cisplatin-based chemotherapy. There was one patient response (5.3%; 95% confidence intervals for response of 0% to 26%). Toxicity was moderate with 5 of 20 (25%) grade 3 or 4 leukopenia, 12 of 20 (60%) grade 3 or 4 granulocytopenia, 1 of 20 (5%) grade 3 thrombocytopenia, 5 of 20 (25%) grade 3 GI toxicity, and 2 of 20 (10%) grade 3 neurotoxicity. There was one toxic death in a patient who developed granulocytopenia and pneumonia after her third course of treatment. This dose schedule of 5-fluorouracil and leucovorin has minimal activity in patients with recurrent epithelial ovarian carcinoma who have received prior cisplatin chemotherapy.

AB - Twenty-one patients with recurrent epithelial ovarian carcinoma not amenable to cure with further surgery or radiotherapy were entered into a Phase II trial utilizing i.v. leucovorin at 20 mg/m2 followed by i.v. 5- fluorouracil at 425 mg/m2 administered daily for 5 days every 4 weeks for the first two courses and then every 5 weeks. Twenty-one patients were entered. Of these, 20 were eligible for toxicity assessment and 19 for response. Five had received prior radiotherapy, and all had received prior cisplatin-based chemotherapy. There was one patient response (5.3%; 95% confidence intervals for response of 0% to 26%). Toxicity was moderate with 5 of 20 (25%) grade 3 or 4 leukopenia, 12 of 20 (60%) grade 3 or 4 granulocytopenia, 1 of 20 (5%) grade 3 thrombocytopenia, 5 of 20 (25%) grade 3 GI toxicity, and 2 of 20 (10%) grade 3 neurotoxicity. There was one toxic death in a patient who developed granulocytopenia and pneumonia after her third course of treatment. This dose schedule of 5-fluorouracil and leucovorin has minimal activity in patients with recurrent epithelial ovarian carcinoma who have received prior cisplatin chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0026470162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026470162&partnerID=8YFLogxK

M3 - Article

C2 - 1449111

AN - SCOPUS:0026470162

VL - 15

SP - 494

EP - 496

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -